Foundation tier · Weight Management
Tirzepatide for Weight Management
A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes and weight management.
Medical Disclaimer
Why Tirzepatide for Weight Management
Role in Protocol
Dual GIP/GLP-1 receptor agonist
Evidence Note
FDA-approved dual incretin agonist. The SURMOUNT-1 trial showed up to 22.5% body weight reduction at the highest dose. Acts on both GIP and GLP-1 receptors for enhanced metabolic effect.
Literature Dosing
2.5-15 mg weekly SC -- SURMOUNT trial titration schedule
Dosing Context
Weight Loss (Zepbound)
Dose
2.5–15 mg
Frequency
weekly
Type 2 Diabetes (Mounjaro)
Dose
2.5–15 mg
Frequency
weekly
Often Used Alongside
Key Safety Notes
Personal or family history of MTC
Same class warning as semaglutide — thyroid C-cell tumour risk in rodents.
MEN 2 syndrome
Predisposition to medullary thyroid carcinoma.
Full Tirzepatide Profile →
Full Weight Management Protocol →